康拓医疗
(688314)
| 流通市值：25.87亿 | | | 总市值：25.87亿 |
| 流通股本：8123.92万 | | | 总股本：8123.92万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 82,490,998.95 | 321,945,239.35 | 240,117,907.83 | 153,339,916.63 |
| 营业收入 | 82,490,998.95 | 321,945,239.35 | 240,117,907.83 | 153,339,916.63 |
| 利息收入 | 0 | 0 | 0 | - |
| 已赚保费 | 0 | 0 | 0 | - |
| 手续费及佣金收入 | 0 | 0 | 0 | - |
| 二、营业总成本 | 49,076,993.48 | 210,820,182.6 | 148,313,124.73 | 96,225,264.83 |
| 营业成本 | 18,346,042.17 | 64,461,081.32 | 47,224,844.11 | 30,521,568.88 |
| 利息支出 | 0 | 0 | 0 | - |
| 手续费及佣金支出 | 0 | 0 | 0 | - |
| 退保金 | 0 | 0 | 0 | - |
| 赔付支出净额 | 0 | 0 | 0 | - |
| 提取保险合同准备金净额 | 0 | 0 | 0 | - |
| 保单红利支出 | 0 | 0 | 0 | - |
| 分保费用 | 0 | 0 | 0 | - |
| 税金及附加 | 1,276,662.53 | 5,232,235.95 | 3,831,167.22 | 2,629,499.01 |
| 销售费用 | 12,607,629.74 | 63,727,045.5 | 44,862,221.3 | 28,840,327.28 |
| 管理费用 | 13,508,804.7 | 56,035,121.14 | 38,710,491.97 | 25,154,584.2 |
| 研发费用 | 4,085,868.04 | 23,904,063.89 | 16,399,769.03 | 10,072,523.69 |
| 财务费用 | -748,013.7 | -2,539,365.2 | -2,715,368.9 | -993,238.23 |
| 其中:利息费用 | 552,381.78 | 2,174,544.63 | 1,689,998.26 | 1,163,248.08 |
| 其中:利息收入 | 1,127,494.65 | 5,221,130.38 | 4,889,343.02 | 2,385,653.79 |
| 加:公允价值变动收益 | 0 | 0 | 0 | - |
| 加:投资收益 | -3,176,167.04 | -12,589,836.25 | -8,118,200.97 | -5,123,859.17 |
| 净敞口套期收益 | 0 | 0 | 0 | - |
| 汇兑收益 | 0 | 0 | 0 | - |
| 资产处置收益 | -115.04 | 463,920.09 | 395,983.5 | 395,983.5 |
| 资产减值损失(新) | -907,082.06 | -5,341,474.23 | -2,409,314.03 | -2,108,666.54 |
| 信用减值损失(新) | -165,890.74 | -1,272,355.17 | 98,342.48 | -66,487.62 |
| 其他收益 | 391,092.06 | 13,329,126.18 | 10,203,005.58 | 8,836,215.13 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 29,555,842.65 | 105,714,437.37 | 91,974,599.66 | 59,047,837.1 |
| 加:营业外收入 | 8,889.75 | 537,496.35 | 392,609.53 | 237,216.35 |
| 减:营业外支出 | 5,248.68 | 247,982.95 | 34,769.48 | 14,789.25 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 29,559,483.72 | 106,003,950.77 | 92,332,439.71 | 59,270,264.2 |
| 减:所得税费用 | 5,863,372.68 | 18,367,960.94 | 16,326,100.09 | 10,993,912.2 |
| 六、净利润 | 23,696,111.04 | 87,635,989.83 | 76,006,339.62 | 48,276,352 |
| 持续经营净利润 | 23,696,111.04 | 87,635,989.83 | 76,006,339.62 | 48,276,352 |
| 终止经营净利润 | 0 | 0 | 0 | - |
| 归属于母公司股东的净利润 | 24,048,177.86 | 88,399,138.29 | 76,713,229.82 | 48,792,223.06 |
| 少数股东损益 | -352,066.82 | -763,148.46 | -706,890.2 | -515,871.06 |
| (一)基本每股收益 | 0.3 | 1.09 | 0.94 | 0.6 |
| (二)稀释每股收益 | 0.3 | 1.09 | 0.94 | 0.6 |
| 八、其他综合收益 | -161,016.57 | -556,787.04 | -641,678.85 | -367,835.15 |
| 归属于母公司股东的其他综合收益 | -162,701.98 | -540,288.98 | -653,007.14 | -362,338.89 |
| 九、综合收益总额 | 23,535,094.47 | 87,079,202.79 | 75,364,660.77 | 47,908,516.85 |
| 归属于母公司股东的综合收益总额 | 23,885,475.88 | 87,858,849.31 | 76,060,222.68 | 48,429,884.17 |
| 归属于少数股东的综合收益总额 | -350,381.41 | -779,646.52 | -695,561.91 | -521,367.32 |
| 公告日期 | 2025-04-29 | 2025-03-28 | 2024-10-29 | 2024-08-14 |
| 审计意见(境内) | | 标准无保留意见 | | |